search
Back to results

Serum VEGF as a Tubal Pregnancy Marker

Primary Purpose

Pregnancy, Ectopic

Status
Completed
Phase
Locations
Brazil
Study Type
Observational
Intervention
Dosage of VEGF serum concentration
Sponsored by
University of Sao Paulo General Hospital
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Pregnancy, Ectopic focused on measuring Pregnancy, Ectopic, Vascular Endothelial Growth Factor A, Pregnancy, Tubal

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria were:

  • women that had a positive hCG test and presented with either abdominal pain or vaginal bleeding; all pregnancies were singletons, spontaneously conceived, with accurate assessments of their gestational age (42 - 56 days from the first day of the last menstrual period). A detailed informed consent was obtained from each patient before the inclusion.

Exclusion Criteria was:

  • non-ampullar tubal pregnancy (surgically confirmed).

Sites / Locations

  • University of Sao Paulo - School of Medicine - General Hospital

Outcomes

Primary Outcome Measures

VEGF serum concentration

Secondary Outcome Measures

Full Information

First Posted
November 22, 2016
Last Updated
November 23, 2016
Sponsor
University of Sao Paulo General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02973230
Brief Title
Serum VEGF as a Tubal Pregnancy Marker
Official Title
Serum Vascular Endothelial Growth Factor (VEGF) As a Marker for Tubal Pregnancy
Study Type
Observational

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
October 2006 (undefined)
Primary Completion Date
September 2007 (Actual)
Study Completion Date
September 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Sao Paulo General Hospital

4. Oversight

5. Study Description

Brief Summary
The aim of the present study was (i) to evaluate whether a single measurement of VEGF would allow us to distinguish between intrauterine pregnancy (normal and abnormal) and EP and (ii) to correlate the levels of VEGF with serum levels of progesterone and β-hCG in each subgroup. Ninety patients were selected from a population of women presenting to the Hospital das Clínicas of the University of São Paulo Medical School from October 2006 until September 2007 and were divided in three subgroups: (i) abnormal (arrested) intrauterine pregnancy (defined as a gestational sac greater than 16 mm of mean diameter without fetal tissue or a embryo greater than 5 mm without embryo cardiac activity); (ii) tubal pregnancy (no evidence of intrauterine pregnancy, presence of a adnexal mass, suboptimal rise of serum hCG levels in 48 hours); all tubal pregnancies were surgically treated and were histologically confirmed, they did not receive any methotrexate treatment before operation; (iii) normal intrauterine pregnancy (intrauterine gestational sac, embryo vitality confirmed). Blood samples were collected by peripheral venous puncture before treatment; a total 15 mL of blood was withdrawn (2 mL for β-hCG, 3mL for progesterone, 10 mL for VEGF determinations). Blood samples for VEGF were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pregnancy, Ectopic
Keywords
Pregnancy, Ectopic, Vascular Endothelial Growth Factor A, Pregnancy, Tubal

7. Study Design

Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Other
Intervention Name(s)
Dosage of VEGF serum concentration
Intervention Description
Blood samples were collected by peripheral venous puncture before treatment; a total 15 mL of blood was withdrawn (2 mL for β-hCG, 3mL for progesterone, 10 mL for VEGF determinations). Blood samples for VEGF were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.
Primary Outcome Measure Information:
Title
VEGF serum concentration
Time Frame
One year

10. Eligibility

Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria were: women that had a positive hCG test and presented with either abdominal pain or vaginal bleeding; all pregnancies were singletons, spontaneously conceived, with accurate assessments of their gestational age (42 - 56 days from the first day of the last menstrual period). A detailed informed consent was obtained from each patient before the inclusion. Exclusion Criteria was: non-ampullar tubal pregnancy (surgically confirmed).
Facility Information:
Facility Name
University of Sao Paulo - School of Medicine - General Hospital
City
Sao Paulo
ZIP/Postal Code
05403010
Country
Brazil

12. IPD Sharing Statement

Learn more about this trial

Serum VEGF as a Tubal Pregnancy Marker

We'll reach out to this number within 24 hrs